Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 positive |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 positive | breast cancer | predicted - sensitive | Rogaratinib | Phase I | Actionable | In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). | detail... | |
FGFR2 positive | ovarian cancer | predicted - sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) inhibited growth in an ovarian cancer cell line expressing FGFR2 in culture (PMID: 27136102). | 27136102 | |
FGFR2 positive | triple-receptor negative breast cancer | sensitive | Alofanib | Preclinical - Cell culture | Actionable | In a preclinical study, Alofanib (RPT835) treatment led to inhibition of cell proliferation in triple-receptor negative breast cancer cell lines expressing FGFR2 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27136102). | 27136102 | |
FGFR2 positive | Advanced Solid Tumor | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, sensitivity to Aprutumab ixadotin (BAY1187982) positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601). | 27543601 | |
FGFR2 positive | breast cancer | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601). | 27543601 | |
FGFR2 positive | stomach cancer | sensitive | Aprutumab ixadotin | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601). | 27543601 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02368951 | Phase I | Aprutumab ixadotin | Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) | Terminated | USA | 2 |
NCT04483505 | Phase I | Fulvestrant + Palbociclib + Rogaratinib | Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST) | Recruiting | ESP | 0 |